Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Huntington's disease (HD) is a progressive neurodegenerative illness for which there is no effective therapy. We examined whether creatine, which may exert neuroprotective effects by increasing phosphocreatine levels or by stabilizing the mitochondrial permeability transition, has beneficial effects in a transgenic mouse model of HD (line 6/2). Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy, and delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice. Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice, whereas the onset of diabetes was markedly delayed. Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations. These results support a role of metabolic dysfunction in a transgenic mouse model of HD and suggest a novel therapeutic strategy to slow the pathological process.

[1]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[2]  A. Laptook,et al.  Journal of Cerebral Blood Flow and Metabolism Age-related Changes in Swine Brain Creatine Kinase-catalyzed 31p Exchange Measured in Vivo Using 31p Nmr Magnetization Transfer , 2022 .

[3]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[4]  H. Nishino,et al.  3-Nitropropionic Acid Increases the Intracellular Ca2+in Cultured Astrocytes by Reverse Operation of the Na+–Ca2+Exchanger , 1997, Experimental Neurology.

[5]  Carlos Cepeda,et al.  Enhanced sensitivity to N‐methyl‐D‐aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease , 1999, Journal of neuroscience research.

[6]  A. Koretsky,et al.  The role of creatine kinase in inhibition of mitochondrial permeability transition , 1997, FEBS letters.

[7]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[8]  M. MacDonald,et al.  Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum , 1997, The Journal of Neuroscience.

[9]  S. Snyder,et al.  Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase , 1995, Annals of neurology.

[10]  P. Nicotera,et al.  Apoptosis, excitotoxicity, and neuropathology. , 1998, Experimental cell research.

[11]  M. Wyss,et al.  Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' for cellular energy homeostasis. , 1992, The Biochemical journal.

[12]  M. Wyss,et al.  Octamer-dimer transitions of mitochondrial creatine kinase in heart disease. , 1999, Journal of molecular and cellular cardiology.

[13]  D. Muller,et al.  Energy Metabolism and Quantal Acetylcholine Release: Effects of Botulinum Toxin, l‐Fluoro‐2,4‐Dinitrobenzene, and Diamide in the Torpedo Electric Organ , 1988, Journal of neurochemistry.

[14]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[15]  Jens Frahm,et al.  Creatine replacement therapy in guanidineoacetate methyltransferase deficiency, a novel inborn error of metabolism , 1996, The Lancet.

[16]  M. Beal,et al.  Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.

[17]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[18]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[19]  Jacqueline K. White,et al.  Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. , 1999, Human molecular genetics.

[20]  P. Bottomley.  Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.

[21]  M. Tarnopolsky,et al.  A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies , 1997, Muscle & nerve.

[22]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[23]  P. Greenhaff.  The nutritional biochemistry of creatine , 1997 .

[24]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[25]  W. Hemmer,et al.  Functional aspects of creatine kinase in brain. , 1993, Developmental neuroscience.

[26]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[27]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[28]  Peter M. G. Munro,et al.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. , 1996, Neuroreport.

[29]  Arend Heerschap,et al.  Altered Ca2+ Responses in Muscles with Combined Mitochondrial and Cytosolic Creatine Kinase Deficiencies , 1997, Cell.

[30]  M. Rudin,et al.  Determination of creatine kinase kinetic parameters in rat brain by NMR magnetization transfer. Correlation with brain function. , 1993, The Journal of biological chemistry.

[31]  Christopher A Ross,et al.  Widespread expression of Huntington's disease gene (IT15) protein product , 1995, Neuron.

[32]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[34]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[35]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[36]  L. Scorrano,et al.  Perspectives on the mitochondrial permeability transition , 1998 .

[37]  T. Wallimann,et al.  The molecular structure of mitochondrial contact sites. Their role in regulation of energy metabolism and permeability transition , 1998, BioFactors.

[38]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[39]  T. Wallimann,et al.  Mitochondrial Creatine Kinase Is a Prime Target of Peroxynitrite-induced Modification and Inactivation* , 1998, The Journal of Biological Chemistry.

[40]  O. Simell,et al.  Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. , 1981, The New England journal of medicine.

[41]  R. Albin,et al.  Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues , 1993, Nature Genetics.

[42]  J. Pettegrew,et al.  Phosphocreatine-dependent Glutamate Uptake by Synaptic Vesicles , 1996, The Journal of Biological Chemistry.

[43]  G Helms,et al.  Creatine Deficiency in the Brain: A New, Treatable Inborn Error of Metabolism , 1994, Pediatric Research.

[44]  S. Lipton,et al.  ■ REVIEW : Excitotoxicity, Free Radicals, Necrosis, and Apoptosis , 1998 .

[45]  Lisa Garrett,et al.  Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA , 1998, Nature Genetics.

[46]  M. Hurlbert,et al.  Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. , 1999, Diabetes.

[47]  O. Andreassen,et al.  Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice , 2000, Journal of neurochemistry.

[48]  M. Beal,et al.  Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.

[49]  B. Ekblom,et al.  Creatine in Humans with Special Reference to Creatine Supplementation , 1994, Sports medicine.

[50]  T. Wallimann,et al.  Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. , 1996, Biochimica et biophysica acta.

[51]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[53]  M. MacDonald,et al.  Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals , 1995, Annals of neurology.

[54]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[55]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[56]  M. Tarnopolsky,et al.  Creatine monohydrate increases strength in patients with neuromuscular disease , 1999, Neurology.

[57]  Bruce R. Rosen,et al.  Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.

[58]  U. Pschorn,et al.  Preincubation with Creatine Enhances Levels of Creatine Phosphate and Prevents Anoxic Damage in Rat Hippocampal Slices , 1995, Journal of neurochemistry.